Back to Journals » Biologics: Targets and Therapy » Volume 3

The old and new therapeutic approaches to the treatment of giardiasis: Where are we?

Authors Busatti HG, Santos JF, Gomes M

Published 5 June 2009 Volume 2009:3 Pages 273—287

DOI https://doi.org/10.2147/BTT.S3943

Review by Single-blind

Peer reviewer comments 4


Haendel GNO Busatti1, Joseph FG Santos2, Maria A Gomes1

1Departmento de Parasitologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil; 2Hospital Santa Casa de Misericórdia de Belo Horizonte, Minas Gerais, Brasil

Abstract: Giardia lamblia is the causative agent of giardiasis, one of the most common parasitic infections of the human intestinal tract. This disease most frequently affects children causing abdominal pain, nausea, vomiting, acute or chronic diarrhea, and malabsorption syndrome. In undernourished children, giardiasis is a determining factor in retarded physical and mental development. Antigiardial chemotherapy focuses on the trophozoite stage. Metronidazole and other nitroimidazoles have been used for decades as the therapy of choice against giardiasis. In recent years many other drugs have been proposed for the treatment of giardiasis. Therefore, several synthetic and natural substances have been tested in search of new giardicidal compounds. This study is a review of drugs used in in vitro and in vivo tests, and also drugs tested in clinical trials (nonrandomized and randomized).

Keywords: Giardia lamblia; treatment; new drugs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]